13. Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details


Clinical trials : 3,340 Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

  
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00799942
(ClinicalTrials.gov)
May 200927/11/2008Open-lable Extension Study on Safety and Efficacy of Neramexane to Treat Congenital and Acquired NystagmusLong-term Open-label Extension Study to Assess the Safety, Tolerability, and Efficacy of Neramexane Mesylate in Congenital Idiopathic Nystagmus and Acquired NystagmusNystagmus, Congenital;Nystagmus, Acquired;Multiple SclerosisDrug: Neramexane mesylateMerz Pharmaceuticals GmbHNULLTerminated18 Years81 YearsBoth48Phase 2United Kingdom